Francesco Pio Cicinato is a PhD student in Pharmaceutical Technology and holds a degree with honors in Pharmaceutical Chemistry and Technology (CTF) from the University of Bari Aldo Moro. His research focuses on the development and characterization of innovative ready-to-use galenic bases for oral and topical administration, aimed at improving the delivery of poorly water-soluble active pharmaceutical ingredients in both human and veterinary medicine. His scientific interests include pharmaceutical technology, formulation development, drug delivery systems, solubility enhancement strategies, pharmaceutical excipients, and bioavailability improvement. Particular attention is devoted to the design of versatile and standardized galenic platforms that can be produced on an industrial scale and supplied to compounding pharmacies, facilitating the preparation of personalized medicines while ensuring quality, reproducibility, and technological reliability. His research aims to bridge pharmaceutical innovation, compounding practice, and industrial manufacturing to support the growing needs of the galenic market.
Francesco Pio Cicinato is a PhD student in Pharmaceutical Technology and holds a degree with honors in Pharmaceutical Chemistry and Technology (CTF) from the University of Bari Aldo Moro. His research focuses on the development and characterization of innovative ready-to-use galenic bases for oral and topical administration, aimed at improving the delivery of poorly water-soluble active pharmaceutical ingredients in both human and veterinary medicine. His scientific interests include pharmaceutical technology, formulation development, drug delivery systems, solubility enhancement strategies, pharmaceutical excipients, and bioavailability improvement. Particular attention is devoted to the design of versatile and standardized galenic platforms that can be produced on an industrial scale and supplied to compounding pharmacies, facilitating the preparation of personalized medicines while ensuring quality, reproducibility, and technological reliability. His research aims to bridge pharmaceutical innovation, compounding practice, and industrial manufacturing to support the growing needs of the galenic market.